Trial Profile
A phase Ib, proof of concept, randomized, double-blind, placebo-controlled, multicentre study to evaluate the safety, tolerability, pharmacokinetics and efficacy of AVR-560 in hepatitis C patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs AVR 560 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- 17 May 2016 New trial record
- 15 May 2014 According to an Alla Chem media release, the final results of this study will be presented in at a major scientific conference in the H2 of 2014.